A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
Alimentary Pharmacology & Therapeutics · 2025-02 · 61 (3) · 456-464
DOI: 10.1111/apt.18377 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 05.11.2024. Verfasst von Maral Amangurbanova und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, MASLD Research Center, University of California at San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Ferritins, Liver Cirrhosis. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Elevated levels of serum ferritin, a marker of hepatic iron overload and inflammation, may be associated with metabolic dysfunction‐associated steatotic liver disease (MASLD) and hepatic fibrosis.
Aim
To determine the prevalence of MASLD and significant hepatic fibrosis among patients with type 2 diabetes mellitus (T2DM) and hyperferritinaemia.
Methods
This is a cross‐sectional analysis of a prospective cohort of 523 adults (64% female) aged 50–80 with T2DM and without a diagnosis of haemochromatosis. MASLD and significant fibrosis were defined as magnetic resonance imaging‐proton density fat fraction (MRI‐PDFF) ≥ 5% and magnetic resonance elastography (MRE) ≥ 3.0 kPa, respectively. Hyperferritinaemia was defined as serum ferritin ≥ 200 ng/mL in females or ≥ 300 ng/mL in males. The primary objective was to determine the prevalence of MASLD and significant fibrosis in hyperferritinaemia.
Results
The mean age and body mass index were 64.1 (±8.1) years and 31.5 (±5.9) kg/m 2 , respectively. The overall prevalence of hyperferritinaemia was 20.5% ( n = 107). The prevalence of MASLD (78.5% vs. 62.1%, p = 0.001) and significant fibrosis (35.5% vs. 22.1%, p = 0.002) were higher in participants with hyperferritinaemia than those without. Hyperferritinaemia remained an independent predictor of MASLD (OR 2.01; 95% CI 1.19–3.39; p = 0.009) and significant fibrosis (OR 2.33; CI 1.43–3.77; p = 0.001), even after adjustment for age, sex, obesity and insulin use.
Conclusion
Approximately 80% of people with hyperferritinaemia and T2DM have MASLD, and more than a third have significant hepatic fibrosis. Hyperferritinaemia may be a useful biomarker for MASLD and significant fibrosis in people with T2DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, MASLD Research Center, University of California at San Diego, La Jolla, California, USA.
- Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore, Singapore.
- Division of Epidemiology, Department of Family Medicine and Public Health, University of California at San Diego, San Diego, California, USA.
ORCID-Profile: Daniel Q Huang, Rohit Loomba
Zitieren
APA
Amangurbanova, M., Huang, D. Q., Noureddin, N., Tesfai, K., Bettencourt, R., Siddiqi, H., Lopez, S. J., Cervantes, V., Madamba, E., & Loomba, R. (2025). A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia. Alimentary Pharmacology & Therapeutics, 61(3), 456-464. https://doi.org/10.1111/apt.18377
Vancouver
Amangurbanova M, Huang DQ, Noureddin N, Tesfai K, Bettencourt R, Siddiqi H, et al. A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia. Alimentary Pharmacology & Therapeutics. 2025;61(3):456-464. doi:10.1111/apt.18377
BibTeX
@article{Amangurbanova2025,
author = {Amangurbanova, Maral and Huang, Daniel Q and Noureddin, Nabil and Tesfai, Kaleb and Bettencourt, Richelle and Siddiqi, Harris and Lopez, Scarlett J and Cervantes, Vanessa and Madamba, Egbert and Loomba, Rohit},
title = {A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
volume = {61},
number = {3},
pages = {456--464},
doi = {10.1111/apt.18377}
}
EUVIMED